Valuation: Mendus AB

Market Cap 418M 43.4M 37.96M 35.02M 32.34M 61.37M 4.14B 62.4M 164M 2.04B 163M 159M 7.01B P/E 2026 *
-4.46x
P/E 2027 * -7.59x
Enterprise Value 97.1M 10.07M 8.81M 8.13M 7.51M 14.24M 961M 14.48M 38.13M 473M 37.82M 37M 1.63B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 0.99x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day+5.57%
1 week+11.62%
Current month+17.79%
1 month+31.66%
3 months+36.40%
6 months+17.38%
Current year+21.79%
1 week 6.06
Extreme 6.06
7.24
1 month 5.05
Extreme 5.05
7.49
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/02/22Buy

Chief Technology Officer

10,000 0.0050%
24/02/22Buy

Chief Executive Officer

84,000 0.0421%
24/02/22Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+5.57%+11.62%-5.01%-33.66% 43.4M
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average +0.16%+0.41%+57.53%+84.63% 24.4B
Weighted average by Cap. -0.48%-0.23%+80.68%+124.29%

Financials

2026 *2027 *
Net sales 8.95M 928K 812K 749K 692K 1.31M 88.55M 1.33M 3.51M 43.62M 3.49M 3.41M 150M 224M 23.29M 20.37M 18.79M 17.35M 32.93M 2.22B 33.48M 88.16M 1.09B 87.44M 85.54M 3.76B
Net income -163M -16.91M -14.79M -13.64M -12.6M -23.9M -1.61B -24.3M -64M -794M -63.47M -62.09M -2.73B -18.59M -1.93M -1.69M -1.56M -1.44M -2.73M -184M -2.77M -7.3M -90.6M -7.24M -7.08M -311M
Net Debt -321M -33.33M -29.15M -26.89M -24.84M -47.13M -3.18B -47.92M -126M -1.57B -125M -122M -5.38B -197M -20.44M -17.88M -16.49M -15.23M -28.9M -1.95B -29.38M -77.36M -960M -76.73M -75.06M -3.3B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
10/07/26 SEK 6.820 +5.57% 37,316
09/07/26 SEK 6.460 -2.12% 33,008
08/07/26 SEK 6.600 +1.54% 71,614
07/07/26 SEK 6.500 -4.27% 51,120
06/07/26 SEK 6.790 +11.13% 80,794
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.820SEK
Average target price
16.00SEK
Spread / Average Target
+134.60%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock